EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis
- Resource Type
- Review Article
- Source
- In
International Immunopharmacology June 2023 119 - Subject
- Language
- ISSN
- 1567-5769